Leonard B. Saltz
#108,739
Most Influential Person Now
Researcher
Leonard B. Saltz's AcademicInfluence.com Rankings
Leonard B. Saltzcomputer-science Degrees
Computer Science
#4045
World Rank
#4255
Historical Rank
Machine Learning
#678
World Rank
#688
Historical Rank
Artificial Intelligence
#880
World Rank
#897
Historical Rank
Database
#1281
World Rank
#1352
Historical Rank
Download Badge
Computer Science
Leonard B. Saltz's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Leonard B. Saltz Influential?
(Suggest an Edit or Addition)Leonard B. Saltz's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. (2008) (2787)
- Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. (2000) (2532)
- Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients (2017) (2165)
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types (2019) (2120)
- Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. (2004) (1737)
- OncoKB: A Precision Oncology Knowledge Base. (2017) (1317)
- Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (2006) (1169)
- Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. (2005) (1127)
- Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (999)
- NCCN Clinical Practice Guidelines in Oncology: colon cancer. (2009) (947)
- Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. (2008) (758)
- Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. (2006) (698)
- Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. (2018) (634)
- NCCN Guidelines Insights: Colon Cancer, Version 2.2018. (2018) (619)
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer (2015) (518)
- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. (2018) (492)
- Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? (2005) (491)
- Developing a cancer‐specific geriatric assessment (2005) (442)
- Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. (2007) (430)
- Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. (2007) (428)
- Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. (2010) (423)
- Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021) (415)
- Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. (2007) (410)
- Rectal cancer. (2007) (396)
- NCCN Task Force Report: Oral chemotherapy. (2008) (396)
- Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. (2009) (376)
- Primary tumor location as a prognostic factor in metastatic colorectal cancer. (2015) (376)
- Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer (2005) (373)
- Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. (2016) (371)
- Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. (2014) (371)
- Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. (1999) (361)
- Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. (1996) (353)
- Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. (2002) (350)
- Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (2018) (328)
- NCCN Clinical Practice Guidelines in Oncology: rectal cancer. (2009) (324)
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing (2017) (321)
- Nonoperative Management of Rectal Cancer With Complete Clinical Response After Neoadjuvant Therapy (2012) (311)
- Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions (2014) (306)
- PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. (2010) (297)
- HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. (2005) (292)
- Neuroendocrine tumors, version 1.2015. (2015) (291)
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. (2019) (289)
- FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. (1992) (287)
- Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. (2007) (279)
- Extracellular Metabolic Energetics Can Promote Cancer Progression (2015) (276)
- NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. (2009) (275)
- Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy (2019) (273)
- Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention (2018) (272)
- Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. (1992) (266)
- Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors (1993) (266)
- Long-Term Prognostic Significance of Extent of Rectal Cancer Response to Preoperative Radiation and Chemotherapy (2002) (264)
- Genomic and biological characterization of exon 4 KRAS mutations in human cancer. (2010) (262)
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803 (2011) (258)
- Comparative genomic analysis of primary versus metastatic colorectal carcinomas. (2012) (257)
- Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. (2002) (254)
- Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. (1999) (254)
- Rate of Pathologic Complete Response With Increased Interval Between Preoperative Combined Modality Therapy and Rectal Cancer Resection (2004) (252)
- Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. (2010) (250)
- Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. (2008) (247)
- Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer (1997) (246)
- Individualized prediction of colon cancer recurrence using a nomogram. (2008) (245)
- Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. (2009) (243)
- A rectal cancer organoid platform to study individual responses to chemoradiation (2019) (242)
- Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations (2018) (242)
- Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. (2002) (242)
- Colon cancer, version 3.2014. (2014) (236)
- Cetuximab therapy and symptomatic hypomagnesemia. (2005) (236)
- NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. (2018) (234)
- The camptothecins (2003) (226)
- Potential regional differences for the tolerability profiles of fluoropyrimidines. (2008) (225)
- NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. (2020) (225)
- The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor (2008) (224)
- Adequacy of 1-cm Distal Margin After Restorative Rectal Cancer Resection With Sharp Mesorectal Excision and Preoperative Combined-Modality Therapy (2003) (222)
- Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients (2015) (221)
- Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. (2008) (217)
- Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. (2001) (216)
- The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances (2003) (214)
- The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances (2003) (214)
- Use of surgery among elderly patients with stage IV colorectal cancer. (2004) (212)
- XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results (2011) (208)
- Pathologic stage is most prognostic of disease‐free survival in locally advanced rectal cancer patients after preoperative chemoradiation (2008) (207)
- Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. (1992) (206)
- Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. (2013) (206)
- PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. (2022) (205)
- Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. (2011) (202)
- Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma (1999) (200)
- Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (2005) (199)
- Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. (2004) (197)
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 (2009) (194)
- Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. (2016) (190)
- Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. (2009) (178)
- A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. (1994) (177)
- Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. (2014) (176)
- Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. (2001) (176)
- Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study (2007) (172)
- Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. (2014) (168)
- Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines (2015) (167)
- BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer (2014) (167)
- Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. (2011) (167)
- Identification of germline genetic mutations in patients with pancreatic cancer (2015) (166)
- Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial (2009) (165)
- Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. (2002) (164)
- Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography (2000) (164)
- Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. (2020) (159)
- Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. (2013) (159)
- Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. (2011) (158)
- Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. (2009) (156)
- Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study (2005) (153)
- Adjuvant therapy for colorectal cancer. (1997) (153)
- Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. (2005) (152)
- Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies (2009) (151)
- Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. (2007) (149)
- Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. (2012) (149)
- Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. (2001) (149)
- Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. (1996) (147)
- Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. (2005) (140)
- Evolving treatment of advanced colon cancer. (2009) (140)
- Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype (2017) (138)
- Developing a cancer-specific geriatric assessment : A feasibility study (2005) (136)
- Rectal Cancer, Version 2.2015. (2015) (133)
- Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer (2012) (132)
- Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. (1993) (132)
- Neuroendocrine and adrenal tumors, version 2.2018 featured updates to the nccn guidelines (2018) (131)
- FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. (2017) (131)
- Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer (2001) (131)
- Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™ (2012) (130)
- Preoperative 5‐fluorouracil, low‐dose leucovorin, and concurrent radiation therapy for rectal cancer (1994) (130)
- Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. (2010) (129)
- Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. (1996) (125)
- NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. (2009) (125)
- Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. (2015) (125)
- Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome (2017) (124)
- Is Nonsmall Cell Type High-grade Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract a Distinct Disease Entity? (2008) (122)
- High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. (2000) (121)
- Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial (2018) (114)
- Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (2007) (114)
- Abdominoperineal resection for rectal cancer at a specialty center (2001) (113)
- Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. (2009) (112)
- Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. (1992) (111)
- A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas (2013) (110)
- Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. (2014) (107)
- CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. (2014) (107)
- Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. (2016) (106)
- Oncologic Outcomes of Salvage Surgery for Epidermoid Carcinoma of the Anus Initially Managed With Combined Modality Therapy (2004) (105)
- A fixed‐ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer (1995) (105)
- The efficacy of preoperative 5‐fluorouracil, high‐dose leucovorin, and sequential radiation therapy for unresectable rectal cancer (1993) (102)
- Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. (2005) (101)
- Overspending driven by oversized single dose vials of cancer drugs (2016) (101)
- A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. (2002) (99)
- Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study (2013) (99)
- Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy (2005) (98)
- A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. (1997) (98)
- Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. (2019) (97)
- L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer (2020) (96)
- Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. (2011) (95)
- A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol (2005) (95)
- Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. (2018) (93)
- Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. (2009) (91)
- Preoperative high‐dose leucovorin/5‐fluorouracil and radiation therapy for unresectable rectal cancer (1991) (90)
- Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. (2012) (90)
- Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. (2005) (89)
- Colon cancer. Clinical practice guidelines in oncology. (2005) (86)
- Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. (2019) (86)
- Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy (2022) (86)
- Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. (2019) (86)
- Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. (2015) (83)
- Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. (2011) (83)
- Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project (2018) (82)
- PD-1 Blockade in Advanced Adrenocortical Carcinoma. (2020) (81)
- Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. (2005) (78)
- XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC) (2007) (77)
- Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. (2011) (77)
- A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. (2008) (77)
- False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. (2014) (77)
- A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. (2014) (76)
- Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. (2012) (76)
- Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) (2004) (74)
- Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. (2012) (73)
- Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. (2013) (73)
- Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. (2008) (72)
- Localized Colon Cancer, version 3.2013 (2013) (72)
- Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. (2009) (71)
- Clinical and molecular characterization of patients with cancer of unknown primary in the modern era (2017) (70)
- The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer (2018) (68)
- Association of family history with cancer recurrence and survival among patients with stage III colon cancer. (2008) (67)
- End points in advanced colon cancer clinical trials: a review and proposal. (2007) (67)
- Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy (2020) (67)
- A phase II trial of alpha‐interferon and 5‐fluorouracil in patients with advanced carcinoid and islet cell tumors (1994) (67)
- Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance) (2014) (67)
- A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. (2009) (66)
- Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. (2010) (65)
- Palliative care in the outpatient oncology setting: evaluation of a practical set of referral criteria. (2011) (64)
- Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. (2019) (62)
- Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. (1998) (61)
- SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance (2018) (61)
- Pulmonary Recurrence Predominates After Combined Modality Therapy for Rectal Cancer: An Original Retrospective Study (2012) (61)
- Impact of smoking on patients with stage III colon cancer (2010) (61)
- A phase 2 study of the insulin‐like growth factor‐1 receptor inhibitor MK‐0646 in patients with metastatic, well‐differentiated neuroendocrine tumors (2012) (60)
- Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. (1993) (59)
- Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. (1993) (59)
- Bevacizumab 5 mg/kg can be infused safely over 10 minutes. (2007) (59)
- Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome (2012) (58)
- Multiparametric MRI in the assessment of response of rectal cancer to neoadjuvant chemoradiotherapy: A comparison of morphological, volumetric and functional MRI parameters (2016) (58)
- Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients. (2016) (58)
- ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. (2014) (57)
- Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. (2011) (57)
- Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. (2006) (56)
- A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. (2001) (55)
- Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). (2015) (54)
- NCCN clinical practice guidelines in oncology. Anal carcinoma. (2010) (54)
- Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). (2004) (54)
- Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 (2005) (54)
- Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer (2014) (53)
- Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations (2017) (53)
- Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. (2017) (53)
- 3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma (2007) (53)
- TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer (2013) (53)
- Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa (2006) (51)
- Anal carcinoma: Clinical practice guidelines in oncology™ (2010) (51)
- PKLR promotes colorectal cancer liver colonization through induction of glutathione synthesis. (2016) (51)
- Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer (2019) (50)
- Adjuvant therapy of cancers of the colon and rectum. (2002) (50)
- Antibody-based therapies for colorectal cancer. (2005) (50)
- Understanding and managing chemotherapy-induced diarrhea. (2003) (50)
- Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection? (2005) (49)
- Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach? (2013) (48)
- Perspectives on Cost and Value in Cancer Care. (2016) (48)
- Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. (2013) (48)
- Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. (2018) (48)
- Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. (2002) (47)
- Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. (2010) (47)
- PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis (2019) (46)
- Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. (2013) (46)
- Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance) (2018) (45)
- Colon cancer clinical practice guidelines in oncology. (2005) (45)
- Marine ω-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance) (2018) (44)
- Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance) (2019) (43)
- Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). (2010) (43)
- Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. (1997) (43)
- Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. (1992) (42)
- New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. (2001) (42)
- Current management of advanced hepatocellular carcinoma. (2008) (42)
- CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. (1996) (42)
- Recurrence Rates and Prognostic Factors in ypN0 Rectal Cancer After Neoadjuvant Chemoradiation and Total Mesorectal Excision (2011) (41)
- Clinical and genetic determinants of ovarian metastases from colorectal cancer (2017) (41)
- Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. (2014) (41)
- Serum 25-Hydroxy Vitamin D and Survival in Advanced Colorectal Cancer: A Retrospective Analysis (2015) (41)
- Progress in cancer care: the hope, the hype, and the gap between reality and perception. (2008) (41)
- Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance) (2017) (41)
- Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? (2005) (41)
- Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. (2017) (40)
- Chemotherapy for large cell lymphoma: a status update. (1990) (40)
- Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF (2015) (40)
- Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803 (2013) (40)
- NCCN Clinical Practice Guidelines Occult primary. (2011) (40)
- A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma (2001) (39)
- Adjuvant Therapy of Colon Cancer: Current Status and Future Directions (2007) (39)
- Study using the NCCN guidelines for palliative care to screen patients for palliative care needs and referral to palliative care specialists. (2013) (38)
- Oral chemotherapeutic agents for colorectal cancer. (2000) (38)
- Tolerability of fluoropyrimidines appears to differ by region. (2006) (38)
- A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. (2001) (37)
- Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. (2018) (37)
- Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database. (2020) (36)
- Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. (2013) (36)
- A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. (2021) (35)
- Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. (2010) (34)
- A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. (1999) (34)
- Organ preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapy. (2015) (34)
- Evaluation of 18F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis (2011) (34)
- Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer (2012) (33)
- Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. (2017) (32)
- Irinotecan in the Treatment of Colorectal Cancer (2002) (32)
- Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center (2020) (32)
- Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. (2017) (31)
- Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? (2011) (30)
- p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803 (2009) (30)
- Safe and cost effective use of alteplase for the clearance of occluded central venous access devices. (2002) (30)
- A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer. (2016) (30)
- How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives. (2017) (30)
- Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients (2017) (30)
- Metastatic colorectal cancer: is there one standard approach? (2005) (29)
- Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors (2015) (29)
- Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors (2009) (29)
- Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. (2016) (29)
- FDG-PET Assessment of Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Is Not Associated With Long-Term Prognosis: A Prospective Evaluation (2012) (29)
- Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966 (2008) (28)
- Colorectal cancer survivors' needs and preferences for survivorship information. (2012) (28)
- 9‐aminocamptothecin by 72‐hour continuous intravenous infusion is Inactive in the treatment of patients with 5‐fluorouracil‐refractory colorectal carcinoma (1997) (27)
- Rectal cancer clinical practice guidelines in oncology. (2005) (27)
- Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer (2021) (26)
- Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer. (2012) (26)
- Clinical Practice Guidelines in Oncology TM (2009) (26)
- Surgery and High-Dose-Rate Intraoperative Radiation Therapy for Recurrent Squamous-Cell Carcinoma of the Anal Canal (2011) (26)
- Frequency, characteristics, and correlates of pain in a pilot study of colorectal cancer survivors 1-10 years post-treatment. (2013) (26)
- Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. (2000) (25)
- Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease (2007) (25)
- The Value of Considering Cost, and the Cost of Not Considering Value. (2016) (25)
- Expression of p27 in Residual Rectal Cancer after Preoperative Chemoradiation Predicts Long-term Outcome (2004) (24)
- Irinotecan in the first-line treatment of colorectal cancer. (1998) (24)
- A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5‐fluorouracil and levamisole after resection of high risk colon cancer (1994) (24)
- The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 (2005) (24)
- Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy. (1996) (24)
- Can money really be no object when cancer care is the subject? (2015) (24)
- Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer. (1992) (23)
- Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). (2009) (23)
- Role of laparoscopy in the initial multimodality management of patients with near- obstructing rectal cancer (2007) (23)
- Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: Meta-analysis of four trials investigating 5-FU and irinotecan. (2006) (23)
- Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. (2020) (23)
- Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas (2018) (23)
- Identification of germline genetic mutations in patients with pancreatic adenocarcinoma. (2013) (22)
- Occult primary, version 3.2014; Featured updates to the NCCN guidelines (2014) (22)
- Colon Cancer , Version 3 . 2014 Clinical Practice Guidelines in Oncology (2014) (21)
- Continuous infusion fluorouracil/leucovorin and bolus mitomycin‐C as a salvage regimen for patients with advanced colorectal cancer (1995) (21)
- MicroRNA-203 predicts human survival after resection of colorectal liver metastasis (2016) (20)
- Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (20)
- Goblet cell carcinoid neoplasm of the appendix: clinical and CT features. (2013) (20)
- Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer. (2015) (20)
- Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance) (2018) (20)
- Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. (2021) (20)
- Lymph Node Metastasis Predicts Disease Recurrence in a Single-Center Experience of 70 Stages 1–3 Appendix Cancers: A Retrospective Review (2015) (19)
- Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. (2020) (19)
- Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival (2017) (19)
- Evolving Treatment of Advanced Colorectal Cancer (2010) (18)
- Adjuvant therapy of colorectal cancer. (1997) (18)
- FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer (2019) (18)
- Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. (2006) (18)
- Occult primary. (2008) (18)
- Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. (2002) (18)
- Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC). (2011) (18)
- Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer (2007) (18)
- MRE11-Deficiency Associated with Improved Long-Term Disease Free Survival and Overall Survival in a Subset of Stage III Colon Cancer Patients in Randomized CALGB 89803 Trial (2014) (18)
- Irinotecan (Campto®) in the treatment of pancreatic cancer (2003) (18)
- Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin. (2000) (18)
- The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia (2018) (18)
- A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803 (2016) (17)
- Irinotecan and cisplatin in upper gastrointestinal malignancies. (1998) (17)
- Adjuvant therapy for colon cancer. (2010) (17)
- Ten-year results of preoperative radiation followed by sphincter preservation for rectal cancer: increased local failure rate in nonresponders. (2006) (17)
- Phase II clinical trial of 13‐cis‐retinoic acid and interferon‐α‐2a in patients with advanced esophageal carcinoma (1999) (17)
- Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (2017) (17)
- Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance) (2018) (17)
- Angiocentric T-cell lymphoma associated with human T-cell lymphotropic virus type I infection. (1990) (17)
- KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. (2011) (17)
- Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short‐term outcomes (2019) (17)
- Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. (2013) (17)
- Phase II trial of gemcitabine in patients with advanced gastric cancer (1994) (17)
- Rectal cancer. Clinical practice guidelines in oncology. (2003) (16)
- Systemic therapy for colon cancer. (2008) (16)
- A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs). (2010) (16)
- Characterization and Clinical Outcomes of DNA Mismatch Repair–deficient Small Bowel Adenocarcinoma (2020) (16)
- 1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab (2011) (15)
- Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. (2021) (15)
- 42 Phase II study of BAY 43-9006 in patients with advanced hepatocellular carcinoma (HCC) (2004) (15)
- Occult primary, version 3.2014. (2014) (15)
- A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC) (2007) (15)
- Colorectal Cancer Treatment: What's Next? (or: Is There Life After EGFR and VEGF?). (2008) (15)
- Adjuvant treatment of colorectal cancer. (1997) (15)
- Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations (2017) (14)
- Colon Cancer , Version 2 . 2018 Featured Updates to the NCCN Guidelines (2018) (14)
- Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. (2019) (14)
- How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors (2007) (14)
- Palliative management of rectal cancer: The roles of chemotherapy and radiation therapy (2004) (14)
- Capecitabine Plus Mitomycin in Patients Undergoing Definitive Chemoradiation for Anal Squamous Cell Carcinoma (2014) (14)
- Cetuximab use without chronic antihistamine premedication. (2006) (14)
- Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†. (2015) (14)
- Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. (2001) (13)
- A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum (2004) (13)
- Colorectal cancer : multimodality management (2002) (13)
- BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy. (2012) (13)
- Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance) (2018) (13)
- Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes (2019) (13)
- Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (2007) (13)
- Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer (2018) (13)
- Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. (2014) (12)
- Systemic therapy for metastatic colorectal cancer. (2013) (12)
- Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. (2021) (12)
- How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives. (2017) (12)
- A phase I trial of intrahepatic Verapamil and doxorubicin. Regional therapy to overcome multidrug resistance (1994) (12)
- Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. (2020) (12)
- Positron emission tomography during preoperative combined modality therapy for rectal cancer may predict ultimate pathologic response: A prospective analysis (2005) (11)
- First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents. (2008) (11)
- A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. (1997) (11)
- NCCN practice guidelines for occult primary tumors (1998) (11)
- Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study). (2009) (11)
- Phase II trial of gemcitabine in patients with advanced gastric cancer. (1994) (11)
- Cancer of the colon (2015) (11)
- A phase I trial of a modified, dose intensive FAMTX regimen (High dose 5‐fluorouracil + doxorubicin + high dose methotrexate + leucovorin) with oral uridine rescue (1996) (11)
- Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings? (2018) (10)
- Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. (2009) (10)
- Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI (2015) (10)
- Another study of how to give fluorouracil? (2003) (10)
- Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies (2014) (10)
- Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance) (2018) (9)
- Role of expression profiling in carcinoma of unknown primary remains unknown. (2013) (9)
- Abstract LB-159: A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC). (2013) (9)
- Bevacizumab in colorectal cancer: it should have worked. (2016) (9)
- Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19 (2020) (9)
- Anal canal cancer. Clinical practice guidelines in oncology. (2003) (9)
- Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. (2016) (9)
- Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis. (2022) (9)
- A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum (2007) (8)
- Genomic profiling and efficacy of anti-EGFR therapy in appendiceal adenocarcinoma. (2016) (8)
- Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance. (2013) (8)
- Colon cancer. (2007) (8)
- Hospitalists on an inpatient tertiary care oncology teaching service. (2015) (8)
- Oral chemotherapy for colorectal cancer: some economic considerations. (2001) (8)
- Combined-modality therapy in the treatment of local-regional esophageal cancer. (1992) (8)
- Outcomes of ICU Admission of Patients With Progressive Metastatic Gastrointestinal Cancer (2020) (8)
- Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance) (2022) (8)
- Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1H MRS study (2013) (8)
- Targeted strategies in the treatment of metastatic colon cancer. (2007) (8)
- A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC). (2015) (8)
- Simplification of bevacizumab (bev) administration: Do we need 90, 60, or even 30 minute infusion times? (2006) (8)
- Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? (1997) (8)
- Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer (2004) (8)
- Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment. (2018) (8)
- Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer. (2017) (8)
- Looking ahead: what will change in colorectal cancer treatment? (2009) (8)
- 30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: characteristics and preventability. (2014) (8)
- Irinotecan: a new agent comes of age. (2001) (7)
- Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors (2020) (7)
- Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why. (2016) (7)
- Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases (2022) (7)
- The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program (2013) (7)
- Granulocyte colony-stimulating factor: effective in ameliorating fluorouracil-based myelosuppression? (1993) (7)
- KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. (2016) (7)
- Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer. (2011) (7)
- Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance). (2017) (7)
- The role of irinotecan in colorectal cancer (1999) (7)
- Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database. (2019) (7)
- Current role of bevacizumab in colorectal cancer. (2009) (7)
- Phase I Study of Two Schedules of Oral S-1 in Combination with Fixed Doses of Oxaliplatin and Bevacizumab in Patients with Advanced Solid Tumors (2011) (7)
- Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer? (2005) (7)
- The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer (2020) (7)
- Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database. (2020) (6)
- Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC). (2014) (6)
- A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC). (2017) (6)
- Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer (2009) (6)
- Management of resectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. (2000) (6)
- American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance). (2017) (6)
- Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance). (2017) (6)
- Conservative management of rectal cancer with local excision and post-op radiation ± chemotherapy (1998) (6)
- The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803 (2008) (6)
- Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database. (2013) (6)
- Biomarkers in colorectal cancer: added value or just added expense? (2008) (6)
- Erratum to: Lymph Node Metastasis Predicts Disease Recurrence in a Single-Center Experience of 70 Stages 1–3 Appendix Cancers: A Retrospective Review (2015) (6)
- Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts. (2014) (5)
- Is adjuvant therapy for stage II colon cancer worthwhile, and for whom? (2008) (5)
- Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database. (2018) (5)
- Value-Added Decisions in Oncology. (2019) (5)
- A phase I trial of cisplatin in hypertonic saline and escalating doses of 5‐fluorouracil by continuous intravenous infusion in patients with advanced malignancies (1990) (5)
- Planned treatment interruptions and chemotherapy-free intervals in the treatment of metastatic colorectal cancer: time to start stopping? (2006) (5)
- Neuroendocrine tumors. (2019) (5)
- Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer. (2012) (5)
- Prevalence of germline genetic alterations in colorectal cancer patients. (2018) (5)
- Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery (2021) (5)
- Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials (2007) (5)
- Randomized phase II study of everolimus (E), leuprolide + letrozole (LL), and E + LL (ELL) in patients (pts) with unresectable fibrolamellar carcinoma (FLC). (2015) (5)
- Antitumor activity in metastatic disease does not predict efficacy in the adjuvant setting. (2012) (5)
- Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal Cancer. (2015) (5)
- Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer (2015) (5)
- A phase II clinical and translational study of MK-2206 in patients with metastatic neuroendocrine tumors (NETs). (2013) (5)
- Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC). (2018) (4)
- Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC). (2012) (4)
- Total neoadjuvant therapy for locally advanced rectal cancer. (2017) (4)
- Cancer of the rectum (2018) (4)
- Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database. (2017) (4)
- BEYOND KRAS: Other Markers and Potential Treatment Strategies for KRAS Mutant and Wild-type Patients (2011) (4)
- 2189 Early onset colorectal cancer - does the difference lie in epigenetics? (2015) (4)
- Trials of locoregional therapies inspired by SABR-COMET (2020) (4)
- Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database. (2016) (4)
- Anal canal cancer clinical practice guidelines in oncology. (2005) (4)
- Re-Evaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. (2021) (4)
- Discharge to Subacute Rehabilitation Facilities Does Not Benefit Patients Hospitalized With Progressive Gastrointestinal Cancer. (2017) (4)
- Levamisole /Fluorouracil A Review of Their Pharmacology and Adjuvant Therapeutic Use in Colorectal Cancer (1991) (4)
- Genetic Screening in All Young Patients With Colorectal Cancer? (2016) (4)
- The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance) (2020) (4)
- Embolization versus embolization and systemic therapy in patients with hepatocellular carcinoma and metastatic disease: A retrospective analysis. (2014) (4)
- MGMT immunohistochemistry (IHC) and exclusion of pancreatic NET (PanNET) patients from treatment with temozolomide-based therapy. (2014) (4)
- Bevacizumab 5mg/kg can be safely infused over 10 minutes (2007) (4)
- The Cost and Value of Anti-Epidermal Growth Factor Receptor Therapies: Let's Not Be Rash. (2015) (4)
- Understanding the Right to Try Act (2019) (3)
- Locally unresectable rectal cancer. American College of Radiology. ACR Appropriateness Criteria. (2000) (3)
- A case for time to tumor progression (TTP) as the primary (1o) efficacy endpoint in 1st-line metastatic colorectal cancer (MCRC) therapy: Correlation of TTP and overall survival (OS). (2004) (3)
- Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. (2013) (3)
- Right versus left: Impact of primary location on survival and cure in patients undergoing hepatic resection for metastatic colon cancer. (2017) (3)
- Doxorubicin Plus Sorafenib in Treatment of Advanced Hepatocellular Carcinoma—Reply (2011) (3)
- Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC). (2015) (3)
- 1412 POSTER Genetic Markers in Relation to Bevacizumab-induced Hypertension (2011) (3)
- Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP). (2014) (3)
- Updated Efficacy Results from XELOX1/NO16966, a Randomized Phase 3 Trial inFirst-Line Metastatic Colorectal Cancer (2007) (3)
- Biologic agents in the treatment of colorectal cancer: the last decade; the lost decade? (2013) (3)
- BRAF mutation as a biomarker in colorectal cancer (2015) (3)
- First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors (2018) (3)
- Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). (2014) (3)
- Factors dictating outcomes in patients with colorectal cancer and peritoneal carcinomatosis: selection, resection, or convection? (2012) (3)
- A rectal cancer model establishes a platform to study individual responses to chemoradiation (2019) (3)
- SMAD4 loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate. (2017) (3)
- Can We Afford That CAR? Confronting the Effect of Novel Immunotherapies on Future Health Care Costs. (2018) (3)
- p 27 Kip 1 in Stage IIIColon Cancer : Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group BProtocol 89803 (2009) (3)
- Second- and third-line treatment options for unresectable metastatic colorectal cancer. (2008) (3)
- 1032 Preliminary results of pre-operative 5-FU, low dose leucovorin (LV), and concurrent radiation therapy (RT) for resectable T3 rectal cancer (1996) (3)
- Cardiac toxicity of 5FU: Does prophylactic telemetry monitoring of patients at increased risk for cardiac toxicity improve safety? A 10-year experience. (2004) (3)
- Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170). (2014) (3)
- Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions (2014) (3)
- The Hardest Weeks of My Life: A Qualitative Study of Experiences, Practice Changes, and Emotional Burden of New York City Oncology Physicians During the COVID-19 Surge in 2020 (2021) (3)
- Precision oncology giveth and precision oncology taketh away. (2019) (3)
- Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC). (2018) (2)
- Drug treatment of colorectal cancer. Current status. (1991) (2)
- Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention. (2016) (2)
- A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors (2022) (2)
- Prognostic factors (PF) in advanced hepatocellular carcinoma (AHCC): Multivariate analysis and comparison between staging systems (SS) in patients (pts) treated at Memorial Sloan-Kettering Cancer Center (MSKCC) (2007) (2)
- Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy. (2018) (2)
- Characterization and clinical outcomes of mismatch repair deficient (dMMR) small bowel adenocarcinoma (SBA). (2019) (2)
- A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma. (2020) (2)
- Author Correction: L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer (2020) (2)
- A phase I study of mFOLFOX6 and ADI-PEG-20 in patients (pts) with advanced hepatocellular carcinoma (HCC) and other gastrointestinal (GI) malignancies. (2017) (2)
- Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. (2019) (2)
- A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management (2022) (2)
- Size Matters (2007) (2)
- Managing chemotherapy-induced diarrhea. (2006) (2)
- Curative-Intent Treatment for Colorectal Liver Metastases: A Medical Oncologist's Perspective. (2012) (2)
- Colorectal cancer. (2015) (2)
- Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer (2019) (2)
- The role of octreotide imaging in detecting neuroendocrine tumors (NETs) in 2010: Do we still need it? (2010) (2)
- Phase I trial of pre-operative combined radiation therapy, 5-FU, and low dose leucovorin for unresectable rectar cancer (1992) (2)
- A prospective analysis of germline alterations (GA) in biliary tract cancer (BTC). (2017) (2)
- Statin use may increase the pathologic complete response rate after neoadjuvant chemoradiation for rectal cancer (2004) (2)
- Management of metastatic colorectal cancer: the impact of clinical trials reported at ASCO 2007 (2008) (2)
- Rectal cancer: presentation with metastatic and locally advanced disease. American College of Radiology. ACR Appropriateness Criteria. (2000) (2)
- Anal cancer. American College of Radiology. ACR Appropriateness Criteria. (2000) (2)
- Novel methodology of response assessment in hepatocellular carcinoma (HCC) -Assessing response by change in tumor enhancement in distinction from conventional means. (2004) (2)
- Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis (2021) (2)
- Comparative genomic analysis of primary versus metastasis in colorectal carcinomas. (2011) (2)
- Top advances of the year in colorectal cancer (2022) (2)
- Occult primary cancer clinical practice guidelines. (2005) (2)
- Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity. (2022) (2)
- Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic colorectal cancer liver metastases (mCRC LM) after progression on all standard chemotherapies. (2014) (2)
- Induction chemotherapy followed by chemoradiotherapy and TME for high-risk locally advanced rectal cancer with and without synchronous resectable metastases. (2012) (2)
- Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance) (2021) (2)
- Targeted therapy for metastatic colorectal cancer: Current challenges and future directions (2007) (2)
- Variability in genomic alterations between right- and left-sided microsatellite stable (MSS) metastatic colorectal cancer and impact on survival. (2017) (1)
- Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database. (2020) (1)
- PCK1 and DHODH drive colorectal cancer liver metastatic colonization and nucleotide biosynthesis under hypoxia (2019) (1)
- Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database. (2018) (1)
- The impact of dietary patterns on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803 (2007) (1)
- Colorectal Cancer Treatments and Therapy Innovations (2013) (1)
- Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer (2022) (1)
- Abstract #1417: Identification and biological characterization of exon 4 KRAS mutations by MALDI-TOF Mass Spectrometry based genotyping (2009) (1)
- Hepatocellular carcinoma (HCC) and bone metastases (Mets). (2015) (1)
- Update: colorectal cancer guidelines. (2003) (1)
- Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1H MRS study (2014) (1)
- Adjuvant therapy report card: Patients with stage II/III colon cancer grade their oncologists. (2009) (1)
- A comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients. (2011) (1)
- Using mutational load in next generation sequencing (NGS) to identify mismatch repair (MMR) deficiency in colorectal cancer (CRC). (2015) (1)
- ‘Tomudex’ (raltitrexed) plus 5-fluorouracil: a promising option for the treatment of patients with metastatic colorectal cancer (1999) (1)
- Receipt and survival outcomes by age following second-line therapy for metastatic CRC (mCRC): Analysis of 5,289 patients from the ARCAD Clinical Trials Program. (2020) (1)
- Prospective identification of potentially actionable molecular alterations in cancers of unknown primary. (2015) (1)
- Incidence of FOLFOX induced amenorrhea in women age 40 and younger with colorectal cancer. (2011) (1)
- Factors influencing outcome after pulmonary resection for colorectal cancer (CRC) metastases in the current era (2008) (1)
- Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database. (2014) (1)
- Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer : A 14-year experience from a specialty service. Authors' reply (2005) (1)
- Evaluation of FDG-PET in pretreatment staging in locally advanced rectal cancer: A prospective study. (2012) (1)
- PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic pyrimidine nucleotide anabolic biosynthesis (2019) (1)
- A Phase 2 Efficacy and Safety, Open-label, Multicenter Study of Imprime PGG Injection in Combination with Cetuximab in Patients with Stage IV KRAS -Mutant Colorectal Cancer (2017) (1)
- Monoclonal Antibodies: The Foundation of Therapy for Colorectal Cancer in the 21st Century? (2004) (1)
- Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer (2022) (1)
- Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials (2020) (1)
- Drug Treatment of Colorectal Cancer (1991) (1)
- Commentary: Somatostatin analogs-How we choose, and why. (2017) (1)
- In Defense of TNT: A Dynamite Strategy. (2021) (1)
- Chemotherapy first, followed by chemoradiation (CRT) and then surgery, in the management of locally advanced rectal cancer (LARC). (2013) (1)
- Induction chemotherapy followed by chemoradiotherapy and total mesenteric excision for locally advanced rectal cancer with resectable metastases. (2013) (1)
- RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response (2015) (1)
- Medical oncology patient readmissions: Are they preventable? (2014) (1)
- A 40-year-old woman with locally advanced rectal cancer and a solitary liver metastasis. (2013) (1)
- Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long-course chemoradiation versus short-course radiation therapy. (2023) (1)
- Characterization of rectal cancer in patients with Lynch syndrome. (2013) (1)
- Does the underlying etiology of HCC effect outcome? A single-institution analysis. (2011) (1)
- Vitamin D levels and survival in colorectal cancer (CRC). (2010) (1)
- How to improve toxicity evaluation in clinical trials? Testing new metrics from irinotecan or oxaliplatin-based treatments in metastatic colorectal cancer (mCRC): A pooled analysis from 2,349 patients in ARCAD database. (2020) (1)
- Biologic agents in the treatment of colorectal cancer: an update (2014) (1)
- Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database. (2011) (1)
- Unusual Tumors of the Colon, Rectum and Anus (2012) (1)
- Bevacizumab : One Treatment for All the Seasons? Author's reply (2008) (1)
- Liver-directed conversion therapy in metastatic colon cancer. (2015) (1)
- The Treatment of Metastatic Colorectal Cancer (2006) (1)
- Induction chemotherapy followed by chemoradiotherapy and TME for high-risk locally advanced rectal cancer. (2011) (1)
- Patterns of recurrence in rectal cancer treated with neoadjuvant chemoradiotherapy and TME. (2010) (1)
- Comparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically? (2018) (1)
- Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min. (2016) (1)
- A case for time to tumor progression (TTP) as the primary (1o) efficacy endpoint in 1st-line metastatic colorectal cancer (MCRC) therapy: Correlation of TTP and overall survival (OS) (2004) (1)
- Effect of discharge to subacute rehabilitation (SAR) on hospitalized patients with progressive gastrointestinal (GI) cancer. (2016) (1)
- Augmentation by Cytochalasin B of Antigen Receptor‐Mediated Activation of Normal and Malignant Human B Lymphocytes (1990) (1)
- Phase I study of oral S-1 in combination with oxaliplatin (oxali) and bevacizumab (bev) in patients with advanced solid tumors (2007) (1)
- Acute hypertensive crisis following octreotide administration in a patient with malignant pheochromocytoma. (1995) (1)
- Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer. (2019) (1)
- 30-Day-or-Sooner Readmissions of Gastrointestinal Medical Oncology Patients Following Cancer Center Inpatient Service Discharge: Characteristics and Preventability (2014) (1)
- Novel methodology of response assessment in hepatocellular carcinoma (HCC) -Assessing response by change in tumor enhancement in distinction from conventional means (2004) (1)
- Surgical cytoreduction in patients with colorectal peritoneal carcinomatosis treated with contemporary chemotherapy. (2010) (1)
- Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors (2009) (1)
- Timing of failure of resected rectal cancer: What is the appropriate duration of postoperative imaging? (2010) (1)
- Evolution in multimodality management of locally advanced rectal cancer. (2017) (1)
- Abstract C174: RAF kinase dimerization mediates clinical acquired resistance to RAF/EGFR inhibition in BRAF V600E colorectal cancer (2015) (0)
- Validity of Adjuvant! Online in elderly patients with stage III colon cancer based on 2,794 patients from the ACCENT database. (2016) (0)
- Is there any significant difference between tumor regression grade systems of rectal cancer (2012) (0)
- Perspectives on the Use of Fluorinated Pyrimidines (2001) (0)
- 100 High dose rate intraoperative brachytherapy for recurrent colorectal cancer (2000) (0)
- Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations (2017) (0)
- Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. (2015) (0)
- FOLFCIS regimen for treatment of cancer of the anal canal. (2018) (0)
- Reply to G. Le Flahec et al. (2017) (0)
- Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database. (2021) (0)
- First stage results of a phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed (POD) on sorafenib (S). (2015) (0)
- Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs). (2021) (0)
- Phase I I T rial o f W eekly I rinotecan P lus C isplatin in A dvanced E sophageal C ancer (1999) (0)
- A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia. (2014) (0)
- 6604 POSTER Updated Survival and Genomic Analysis of a Phase II Trial of Temsirolimus in Advanced Neuroendocrine Carcinomas (2011) (0)
- Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance) (2022) (0)
- Feasibility of screening hospitalized cancer patients for palliative care. (2012) (0)
- Lack of Availability and Efficacy of Phase I and Basket Trials for Patients with Gastrointestinal Cancers. (2019) (0)
- p27 Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 (2011) (0)
- NEUROENDOCRINE TUMORS (2007) (0)
- ASCO Annual Meeting Promises Important Updates for CRC Research (2014) (0)
- A situation where hepatocellular carcinoma (HCC) may be more common in women than men: Clinical and genetic patterns of non risk-factored HCC. (2017) (0)
- Combination Chemotherapy by Infusion in Hematological Malignancies (1991) (0)
- Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma. (2012) (0)
- Benefit of early-phase targeted, basket, and immune-based trials for patients with chemorefractory gastrointestinal (GI) cancers. (2019) (0)
- Rectal Cancer NCCN Rectal Cancer Panel Members Continue (0)
- Clinical prognostic factors and genomic analysis of ovary metastases (mets) from colorectal cancer (CRC). (2016) (0)
- Changing physician practice and introduction of treatment guidelines for colorectal cancer: An analysis of 162,477 patients (2004) (0)
- Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program. (2020) (0)
- Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients. (2015) (0)
- Size matters. What can we learn from a small randomized trial? (2007) (0)
- The rate and risk of secondary pelvic malignancies (SPM) in patients treated with definitive radiation for locally advanced rectal cancer. (2021) (0)
- Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. (2015) (0)
- Occult primary: Clinical practice guidelines in oncology (2008) (0)
- Use of immunotherapy (IO) supplied free of charge to cancer patients. (2018) (0)
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types (2019) (0)
- Adjuvant C hemotherapy U se f or M edicare B eneficiaries With S tage I I C olon C ancer (2002) (0)
- Bevacizumab in first-line therapy in lung metastases of colorectal cancer: An ARCAD pooled analysis. (2023) (0)
- Combination chemotherapy: the fallback position? (2008) (0)
- Author's Response. (2018) (0)
- Immediate post-thermal ablation biopsy of colorectal liver metastases to predict oncologic outcomes. (2020) (0)
- IClinical Trial of the Sequential Combination of Irinotecan Followedby Flavopiridol (2005) (0)
- Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer (2006) (0)
- Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database. (2018) (0)
- [Oxaliplatin: high activity at all stages of colon carcinomas]. (2003) (0)
- Characterization of Rectal Cancer in Patients With Lynch Syndrome (2015) (0)
- Characterization of colorectal cancer (CRC) in Lynch syndrome (LS) patients with MSH6 or PMS2 mutations. (2013) (0)
- Erratum to: Drug Treatment of Colorectal Cancer (1992) (0)
- Adjuvant therapy for colorectal cancer background and results of surgical resection (1997) (0)
- Molecular landscape of fibrolamellar carcinoma (FLC): Beyond the DNAJB1-PRKACA chimera. (2017) (0)
- Reply to S. Boutayeb et al. (2020) (0)
- Octreotide A cetate L ong-Acting F ormulation Versus O pen-Label S ubcutaneous O ctreotide Acetate i n M alignant C arcinoid S yndrome (2007) (0)
- Total neoadjuvant chemotherapy to facilitate delivery and tolerance of systemic chemotherapy and response in locally advanced rectal cancer. (2017) (0)
- Induction Chemotherapy Reduces Patient-Reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiation Therapy for Rectal Cancer (2017) (0)
- PD-0009 Primary Tumor Location is a Major Independent Prognostic Factor for Mcrc Patients (2012) (0)
- Capecitabine monotherapy in metastatic colorectal cancer – Authors' reply (2001) (0)
- Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer (2018) (0)
- Clinical assessment following preoperative combined modality therapy (CMT) for rectal carcinoma does not accurately predict pathologic response: A prospective analysis. (2004) (0)
- An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. (2017) (0)
- Prostate Cancer: When to Order an MRI (2018) (0)
- Intensity Modulated Radiotherapy for Anal Squamous Cell Carcinomas: Preliminary Analysis of Toxicity and Outcomes (2009) (0)
- Abstract 4380: Integrative genomics analysis of metastatic colorectal cancer (2017) (0)
- Variability in response definition and confirmation practices in randomized phase II and III trials in colorectal cancer (2004) (0)
- 91. Neuroendocrine Tumors (2014) (0)
- Oxaliplatin can be safely infused at a rate of 1mg/m2/min. (2015) (0)
- Book Review: Colorectal Cancer: Evidence-Based Chemotherapy Strategies. (2006) (0)
- Advanced Colorectal Cancer Second-and Third-Line Treatment Options for Unresectable Metastatic Colorectal Cancer (0)
- Feasibility of screening hospitalized patients for palliative care. (2012) (0)
- Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database. (2019) (0)
- Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials (2022) (0)
- Recurrence rates of resected appendix carcinoid tumors: A 20-year experience at Memorial Sloan Kettering Cancer Center. (2016) (0)
- Deletions in HSP110 T17 and patient prognosis in stage III microsatellite instable (MSI) colon cancers: Findings from CALGB 89803 and NCCTG N0147. (2016) (0)
- Predictors of site-specific recurrence following combined modality therapy for locally advanced rectal cancer. (2010) (0)
- Multiplatform profiling of a fibrolamellar carcinoma cohort. (2014) (0)
- Abstract CT062: A phase I dose escalation study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) in patients with advanced gastrointestinal (GI) tumors (2018) (0)
- Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. (2019) (0)
- Clinical C haracteristics a nd O utcomes F rom a n I nstitutional Series o f A cinar C ell C arcinoma o f t he P ancreas a nd Related T umors (2002) (0)
- Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database. (2018) (0)
- Colorectal cohort analysis from the Intraperitoneal Chemotherapy After Cytoreductive Surgery for Peritoneal Metastasis (ICARuS) clinical trial. (2023) (0)
- A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC). (2018) (0)
- OP-JNCI190243 438..442 (2020) (0)
- Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. (2022) (0)
- Accent-based nomograms (NGs) to predict time to recurrence (TTR) and overall survival (OS) in stage III colon cancer (CC). (2013) (0)
- Somatic tumor profiling of DNA mismatch repair deficient (MMR-D) colorectal cancers (CRC). (2016) (0)
- Pitfalls of CA-125 Levels in the Preoperative Work-Up of Ovarian Masses (2007) (0)
- Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations (2023) (0)
- Abstract A12: L1CAM defines the regenerative origin of metastasis initiating cells in colorectal cancer (2020) (0)
- Determinants of early mortality in 37,568 colon cancer patients participating in 25 clinical trials of the ACCENT database. (2015) (0)
- Outcomes of ICU admission of patients with progressive metastatic gastrointestinal (GI) cancer. (2016) (0)
- Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC). (2016) (0)
- NCCN Rectal Cancer , Version 2 . 2018 Clinical Practice Guidelines in Oncology (2018) (0)
- Clinical assessment following preoperative combined modality therapy (CMT) for rectal carcinoma does not accurately predict pathologic response: A prospective analysis (2004) (0)
- Gemcitabine (gem) as salvage therapy in metastatic colorectal adenocarcinoma (mCRC). (2011) (0)
- Author reply (0)
- Management of metastatic colorectal cancer. (2014) (0)
- Evaluation of Bevacizumab in the Adjuvant Treatment of Colon Cancer (2010) (0)
- Would you do it again? The perspectives of patients as they receive and recover from adjuvant therapy for stage II/III colon cancer. (2010) (0)
- Neuroendocrine TumorsPractice Guidelines in Oncology (2012) (0)
- Commentary (Saltz)—Cetuximab-Associated Infusion Reactions: Pathology and Management (2006) (0)
- UnitedHealthcare's Episode-Based Payment Model Program Cuts Cost. (2015) (0)
- The system over-rewards incremental gains. (2014) (0)
- Variability in response definition and confirmation practices in randomized phase II and III trials in colorectal cancer. (2004) (0)
- Small Bowel Adenocarcinoma, Version 1.2020 (2019) (0)
- Low objective response and high toxicity to single-agent mitotane in patients with metastatic adrenocortical carcinoma (ACC): A 25 year experience at MSKCC. (2015) (0)
- "Months, not years": Impact of clinical discussions of advanced cancer life-expectancy on patient illness understanding. (2015) (0)
- Treatment and Survival Outcomes by Age Following Second-Line Therapy for Metastatic CRC (mCRC): Analysis of 13,149 Patients from the ARCAD Clinical Trials Program (2021) (0)
- Perspectives on fluorinated pyrimidine use in gastrointestinal and breast oncology. (2001) (0)
- Survival outcomes and end of life use of immunotherapy (IO) supplied free of charge for cancer patients. (2018) (0)
- Book Review: Regulation of Gene Expression: Molecular Mechanisms. (2006) (0)
- Tumor of Unknown Primary Site (2010) (0)
- Anal Carcinoma , Version 2 . 2018 Clinical Practice Guidelines in Oncology (2018) (0)
- Treating Metastatic Colorectal Cancer While Questions Remain Unanswered (2007) (0)
- Surgery: Apples and oranges: the low and mid versus the upper rectum (2009) (0)
- Prognostic role of C-reactive protein levels in patients with hepatocellular carcinoma undergoing sorafenib therapy. (2014) (0)
- Statin use may increase the pathologic complete response rate after neoadjuvant chemoradiation for rectal cancer. (2004) (0)
- BRAF mutations in patients with well-differentiated pancreatic neuroendocrine tumors (WD pNETs). (2015) (0)
- Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer (2013) (0)
- Treatment Options for Patients With Unresectable Colorectal Cancer With Wild-Type KRAS (2012) (0)
- Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database. (2017) (0)
- Chapter 88 – Advances in systemic therapy for hepatocellular carcinoma (2012) (0)
- Actionable alterations (AA) in gastrointestinal (GI) cancers: Rate of detection and receipt of matched therapies (MT). (2020) (0)
- Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. (2013) (0)
- Factors guiding selection of treatment in metastatic colorectal cancer. (2023) (0)
- Clinical Use of Camptosar (CPT-11) (1997) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Leonard B. Saltz?
Leonard B. Saltz is affiliated with the following schools:
